Results 151 to 160 of about 26,183 (176)

Correction to: Progress in Access and Oral Polio Vaccine Coverage Among Children Aged <5 Years in Polio Campaigns After the Political Change in Afghanistan. [PDF]

J Infect Dis
europepmc   +1 more source

Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study. [PDF]

Lancet Infect Dis
Bashorun AO, Kotei L, Jawla O, Jallow AF, Saidy AJ, Kinteh MA, Kujabi A, Jobarteh T, Kanu FJ, Donkor SA, Ezeani E, Fofana S, Njie M, Ceesay L, Jafri B, Williams A, Jeffries D, Kotanmi B, Mainou BA, Ooko M, Clarke E.   +20 more
europepmc   +1 more source

Risk-free polio vaccine: Recombinant expression systems for production of stabilised virus-like particles

Sherry L, Bahar MW, Porta C, Fox H, Grehan K, Nasta V, Duyvesteyn HME, de Colibus L, Marsian J, Murdoch I, Ponndorf D, Kim S, Shah S, Carlyle S, Swanson JJ, Matthews S, Nicol C, Lomonossoff GP, Macadam AJ, Fry EE, Stuart DI, Stonehouse NJ, Rowlands DJ.   +22 more
europepmc   +1 more source

State polio vaccine programs.

, 1955
Otis L. Anderson
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Designing spatial and temporal control of vaccine responses

Nature Reviews Materials, 2021
Shih Hao Ou, Wei Luo, Bali Pulendran
exaly  

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Nature Reviews Clinical Oncology, 2021
Aakash Desai, Justin F Gainor, Aparna M Hegde   +2 more
exaly  

SARS-CoV-2 variants, spike mutations and immune escape

Nature Reviews Microbiology, 2021
William T Harvey, Alessandro Maria Carabelli, Benjamin C Jackson   +2 more
exaly